qedtx.com

Qed Therapeutics

Qed Therapeutics's email is info@QEDTx.com and Qed Therapeutics's phone number is 1-877-280-5655 .

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Their lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
View Top Employees for Qed Therapeutics
img Website qedtx.com
img Industry Biotechnology
img Location Palo Alto, California, United States
img Employees 78
img Founded 2018
img HQ 421 Kipling Street
img Phone 1-877-280-5655
img Email info@QEDTx.com
img Funding 65,000,000 USD
img Competitors Roche, Agilent Technologies, Amgen, Genentech, Eurofins, Gilead Sciences,
img Website qedtx.com
img Industry Biotechnology
img Location Palo Alto, California, United States
img Employees 78
img Founded 2018
img LinkedIn linkedin.com/company/qed-therapeutics
img HQ 421 Kipling Street
img Phone 1-877-280-5655
img Email info@QEDTx.com
img Funding 65,000,000 USD

Top Qed Therapeutics Employees